Loading…

A mammary adenocarcinoma murine model suitable for the study of cancer immunoediting

Cancer immunoediting is a dynamic process composed of three phases: elimination (EL), equilibrium (EQ) and escape (ES) that encompasses the potential host-protective and tumor-sculpting functions of the immune system throughout tumor development. Animal models are useful tools for studying diseases...

Full description

Saved in:
Bibliographic Details
Published in:Journal of biomedical science 2014-05, Vol.21 (1), p.52-52, Article 52
Main Authors: Pagura, Lucas, Cáceres, Juan Manuel, Cardinale, Albertina, Scharovsky, Olga Graciela, Masso, Ricardo José Di, Zacarías-Fluck, Mariano Federico, Rico, María José, Rozados, Viviana Rosa
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cancer immunoediting is a dynamic process composed of three phases: elimination (EL), equilibrium (EQ) and escape (ES) that encompasses the potential host-protective and tumor-sculpting functions of the immune system throughout tumor development. Animal models are useful tools for studying diseases such as cancer. The present study was designed to characterize the interaction between mammary adenocarcinoma M-406 and CBi, CBi- and CBi/L inbred mice lines. The mammary adenocarcinoma M-406 developed spontaneously in a CBi mouse. CBi/L and CBi- mice were artificially selected for body conformation from CBi. When CBi mice are s.c. challenged with M-406, tumor growths exponentially in 100% of animals, while in CBi- the tumor growths briefly and then begins a rejection process in 100% of the animals. In CBi/L the growth of the tumor shows the three phases: 51.6% in ES, 18.5% in EQ and 29.8% in EL. The results obtained support the conclusion that the system M-406 plus the inbred mouse lines CBi, CBi- and CBi/L, is a good murine model to study the process of tumor immunoediting.
ISSN:1423-0127
1021-7770
1423-0127
DOI:10.1186/1423-0127-21-52